4502 — Takeda Pharmaceutical Share News
0.000.00%
Last trade - 00:00Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Brief: Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds (updated)
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
US jury to decide if Takeda delayed generic constipation drug
Bain-backed Tanabe Pharma targets three new drug launches a year in Japan
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring (updated)
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
US FDA approves BeOne's drug for a type of blood cancer (updated)
Table: Takeda Pharma -2025/26 parent results
Table: Takeda Pharma -2025/26 group results (IFRS)
Morning Bid Europe: Locked in a stalemate with Iran, Trump heads to China
Brief: British Columbia Reimburses Revestive® (Teduglutide For Injection) For The Treatment Of Short Bowel Syndrome
Takeda's immune disease drug meets main goal of trial (updated)
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Brief: Takeda Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of Tak-881 In Primary Immunodeficiency Disease (Pid)
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Spyre's inflammatory bowel drug shown to reduce disease activity in mid-stage study (updated)
Spyre's inflammatory bowel drug reduces disease activity in mid-stage study